Brief: Novartis Temporarily Pausing Screening, Randomization And Treatment Across Rapcabtagene Autoleucel Trials In Autoimmune Diseases
01/09/2026 08:26
BRIEF-Novartis Temporarily Pausing Screening, Randomization And Treatment Across Rapcabtagene Autoleucel Trials In Autoimmune Diseases Sept 1 (Reuters) - Novartis AG NOVN.S:
NOVARTIS- TEMPORARILY PAUSING SCREENING, RANDOMIZATION AND TREATMENT ACROSS RAPCABTAGENE AUTOLEUCEL TRIALS IN AUTOIMMUNE DISEASES
NOVARTIS AG -THE RAP-CEL PROGRAM IN ONCOLOGY IS NOT AFFECTED BY THIS HALT
NOVARTIS AG-PAUSE FOLLOWS NOTIFICATION OF 3 SERIOUS IMMUNE EFFECTOR CELL ASSOCIATED HEMOPHAGOCYTIC SYNDROME EVENTS, RESULTING COMPLICATIONS LED TO FATAL OUTCOMES
Source text: [ID:]
Further company coverage: NOVN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant